Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume – Should You Buy?

Shares of Bavarian Nordic (OTCMKTS:BVNRY) saw unusually-strong trading volume on Tuesday. 3,696 shares changed hands during trading, an increase of 11% from the previous session’s volume of 3,328 shares. The stock last traded at $12.00 and had previously closed at $11.7750.

Bavarian Nordic Stock Performance

The firm has a 50-day moving average price of $10.97 and a 200-day moving average price of $10.06. The stock has a market cap of $2.89 billion, a PE ratio of 12.27 and a beta of 1.25.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its quarterly earnings data on Friday, August 21st. The company reported $0.46 EPS for the quarter. The company had revenue of $316.47 million for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.

Bavarian Nordic Company Profile

Bavarian Nordic A/S is a Denmark-based biotechnology and vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. The company supplies products to government agencies, public-health organizations, healthcare providers and private-sector customers in markets around the world.

Its best-known product is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for travelers and other infectious-disease risks, including products targeting rabies, tick-borne encephalitis, typhoid and cholera, as well as selected pediatric and adult immunization needs.

Founded in 1994 and headquartered in Copenhagen, Bavarian Nordic has expanded from a vaccine research company into an international commercial vaccine manufacturer.